Results 41 to 50 of about 10,352 (222)

Co-Treatment with Steroid and Dupilumab for Eosinophilic Chronic Rhinosinusitis after Eosinophilic Pneumonitis Caused by Dupilumab

Ear, Nose & Throat Journal
Eosinophilic chronic rhinosinusitis (ECRS) is a Type 2 inflammatory disease that manifests as chronic inflammation of the paranasal sinus. IL-4/IL-13 receptor monoclonal antibodies (dupilumab) to suppress Type 2 inflammation have become a good treatment ...
Takato Sudo MD, Takeshi Tsuda MD, PhD, Masaki Hayama MD, PhD, Kazuya Takeda MD, PhD, Sho Obata MD, Ayaka Nakatani MD, Yuta Amano MD, Soichiro Fujii MD, Hiroko Fukata MD, Hidenori Inohara MD, PhD   +9 more
doaj   +1 more source

Effect of dupilumab on otitis media associated with eosinophilic chronic rhinosinusitis

Brazilian Journal of Otorhinolaryngology
Objective: Eosinophilic Otitis Media (EOM) is an intractable disease caused by type 2 inflammation, such as Eosinophilic Chronic Rhinosinusitis (ECRS) and bronchial asthma. Biologics have recently been used to treat ECRS and bronchial asthma.
Seiichiro Kamimura, Keisuke Ishitani, Ryota Morozumi, Eiji Kondo, Takahiro Azuma, Go Sato, Yoshiaki Kitamura   +6 more
doaj   +1 more source

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl, Jonathan Grigg, Lubna Abuqayyas, Piotr Kuna, Gillian Hunter, Beata Pawlikowska, Jacob Leander, Michael Levin, Atul Gupta, James Paton, Katharine C. Pike, Jane R. Parnes, Gun Almqvist, Stephanie L. Roseti, on behalf of the study investigators   +14 more
wiley   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

A Role of the IL‐13 Signal and Type 2 Conventional Dendritic Cell in the Atopic March

Barrier Immunity, EarlyView.
ABSTRACT Allergic diseases such as atopic dermatitis (AD), asthma, and food allergy originate at epithelial barrier surfaces, where environmental insults trigger immune responses. This review emphasizes the crucial role of epithelium‐derived alarmins, especially IL‐33 and TSLP, as innate danger signals (DAMPs) that establish a local type 2 milieu ...
Masato Kubo
wiley   +1 more source

Inflammatory Factors in Allergic Rhinitis: A 20‐Year Bibliometric Mapping and Emerging Trends

Flavour and Fragrance Journal, EarlyView.
This figure illustrates the bibliometric process and results of research on inflammatory factors of allergic rhinitis from 2004 to 2024 including data screening, global distribution, collaborative networks and the evolution of research hotspots. ABSTRACT Allergic rhinitis (AR) is driven by a network of inflammatory mediators released by mast cells ...
Shanshan Jing, Fengying Zhang, Qiqi Liu
wiley   +1 more source

A case of recurrent chronic eosinophilic pneumonia after switching from benralizumab to dupilumab

Respiratory Medicine Case Reports
Dupilumab inhibits interleukin-4Rα and suppresses type 2 inflammation. Careful administration of dupilumab is required because it increases the blood eosinophil count secondary to a decrease in local eosinophil counts, sometimes resulting in eosinophilic
Daiki Nakashima, Eri Mori, Nobuyoshi Otori   +2 more
doaj   +1 more source

The use of dupilumab in severe atopic dermatitis during pregnancy: a case report

Allergy, Asthma & Clinical Immunology, 2022
Background Atopic dermatitis is a common chronic skin disease that can occur in pregnancy. Current treatments include topical and systemic glucocorticoids and cyclosporine.
Nabeel H. Akhtar, Touraj Khosravi-Hafshejani, Daud Akhtar, Gurbir Dhadwal, Amin Kanani   +4 more
doaj   +1 more source

Assessment of MUcociLiary Transport timE in CRSwNP Patients in Treatment With Dupilumab: AMULET Study

International Forum of Allergy &Rhinology, EarlyView.
Alessia Giorli, Fabio Ferretti, Antonio Romano, Marco Casiraghi, Mariella Scarano, Paolo Farneti, Giacomo Sollini, Marco Mandalà, Ernesto Pasquini, Cesare Biagini   +9 more
wiley   +1 more source

Successful treatment of eosinophilic esophagitis with upadacitinib prescribed for atopic dermatitis

JPGN Reports, EarlyView.
Abstract We describe a pediatric patient treated with upadacitinib for atopic dermatitis (AD) who subsequently achieved sustained clinical and histologic remission of eosinophilic esophagitis (EoE). Upadacitinib is an oral small molecule selective Janus kinase 1 inhibitor that inhibits janus kinase‐signal transduction and activation of transcription ...
Nathalie Nguyen, Maureen Bauer
wiley   +1 more source